The World Health Organization (WHO) on Wednesday said it is resuming clinical trials of the anti-malaria drug, hydroxychloroquine, to ascertain its effectiveness in treating Covid-19. WHO announced this resumption a week after the executive group of the Solidarity trial paused the hydroxychloroqu
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp